Skip to main content
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · IEX Real-Time Price · USD
1.500
-0.020 (-1.32%)
At close: Jul 19, 2024, 4:30 PM
1.420
-0.080 (-5.33%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

Inhibikase Therapeutics Revenue

Inhibikase Therapeutics had revenue of $195.98K in the twelve months ending March 31, 2024, with 38.08% growth year-over-year. In the year 2023, Inhibikase Therapeutics had annual revenue of $260.50K with 111.03% growth.

Revenue (ttm)
$195.98K
Revenue Growth
+38.08%
P/S Ratio
55.23
Revenue / Employee
$21,776
Employees
9
Market Cap
10.82M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023260.50K137.06K111.03%
Dec 31, 2022123.44K-2.98M-96.02%
Dec 31, 20213.10M2.40M343.92%
Dec 31, 2020698.47K-424.27K-37.79%
Dec 31, 20191.12M-2.92M-72.22%
Dec 31, 20184.04M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

IKT News

More News